Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 3/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | NMT1 | P30419 | 3/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10304673 | 0.91 | CHRNB2 (0.43) | HRH1CHRM3SLC6A2ACHEFAAH | |
| SCHEMBL632508 | 0.81 | ACHE (0.41) | ACHEFAAHMGLLHTR1A | |
| SCHEMBL7278431 | 0.80 | FAAH (0.46) | HRH1NMT1FAAH | |
| SCHEMBL7278648 | 0.79 | ACHE (0.45) | CHRM3SLC6A2NMT1ACHEFAAH | |
| Hydrochloric Acid SCHEMBL7280489 | 0.79 | FAAH (0.45) | HRH1NMT1FAAH | |
| Hydrochloric Acid SCHEMBL7280360 | 0.78 | ACHE (0.44) | CHRM3SLC6A2ACHEFAAHMGLL | |
| SCHEMBL632513 | 0.78 | ACHE (0.39) | ACHEFAAHMGLL | |
| SCHEMBL9411204 | 0.78 | ACHE (0.62) | SLC6A2ACHEFAAHMGLL | |
| SCHEMBL911842 | 0.77 | SLC6A4 (0.44) | SLC6A2ACHEFAAHMGLLSLC6A3 | |
| SCHEMBL911841 | 0.77 | SLC6A4 (0.44) | SLC6A2ACHEFAAHMGLLSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545682-B2 | Heterocyclic derivatives as P2X7 receptor antagonists | BREYE THERAPEUTICS APS (DK) | 2026-02-10 | — | — | US | claimed |
| US-20240034737-A1 | Heterocyclic Derivatives as P2X7 Receptor Antagonists | BREYE THERAPEUTICS APS (DK) | 2024-02-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240034737-A1 | Heterocyclic Derivatives as P2X7 Receptor Antagonists | P2RX7, P2RX3, P2RX1 | HRH1 421/4885CHRM3 499/4885SLC6A2 1205/4885 |
| US-12545682-B2 | Heterocyclic derivatives as P2X7 receptor antagonists | P2RX7, P2RX3, P2RX1 | HRH1 589/4885CHRM3 63/4885SLC6A2 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.